Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Sniper007on Feb 20, 2013 3:13am
213 Views
Post# 21014322

RE: RE: RE: Shire/AZ/Forest/BTI

RE: RE: RE: Shire/AZ/Forest/BTI

In the article posted by amillionorbust there were a few things that popped out at me after re-reading the article.

Some Opportunities:

"Soriot, a former Roche Holding AG executive who took over as CEO of AstraZeneca in October, said in a Jan. 31 interview that the company planned to revive growth by focusing on its existing businesses, and supplementing development with acquisitions of about $3 billion to $4 billion and licensing deals of as much as $600 million."

"He will unveil the company’s strategy to analysts on March 21 in New York."

"Given the “substantial” scale of AstraZeneca’s coming revenue gap, acquisitions and partnerships “will be forthcoming and will not come cheap,” Credit Suisse Group AG analysts, including Luisa Hector and Kerry Holford, wrote in a Feb. 1 note. It could take purchases of $20 billion to make up the sales shortfall, according to their note."

New Treatments:

“They’ve got to buy something with infrastructure they don’t already have,” he said

"In addition to Dublin-based Shire, Kepler’s Wenner said Forest, with a market value of $9.4 billion, also could be a good fit for AstraZeneca because they both have treatments for infections and respiratory and central nervous system diseases."

No Time:

"Soriot’s desire to preserve AstraZeneca’s credit rating -- which is AA- by Standard & Poor’s, the fourth-highest level of investment grade -- could limit the size of any deal. Still, with $7.7 billion of cash and $10.3 billion in debt, the company could spend $10 billion without triggering a downgrade, said Olaf Toelke, a credit analyst with S&P."

"“I would expect some quick changes,” Toelke said in a phone interview. “They’re running out of time. They really need to do something.”"

"“They’re going to have to spend a lot of money to get the assets that really count,” Malik said. “If they want to capture the imagination of shareholders, they should bite the bullet.”"

I've added these excerpts to fuel the buyout speculation, which to me, seems only a matter of time.

It's possible March 21 could be an important date...

What about Forest?  They also have treatments for CNS diseases.  I'm guessing they might need a little Transcend.  They could be in the mix too.

Sniper

 

 

Bullboard Posts